What GLP-2 is
GLP-2 is an endogenous gut peptide involved in intestinal growth and barrier-related signaling and helps explain GLP-2 analog therapies.
GLP-2 is grouped under Fat Loss + GLP-1s / Endogenous / Biology / Approved / Clinical on PeptideFactCheck because it becomes relevant when people move from appetite peptides into gut-repair and intestinal-adaptation biology.
The useful starting point is to separate the molecule itself from the internet story around it. It becomes relevant when people move from appetite peptides into gut-repair and intestinal-adaptation biology.
Why people keep looking it up
It becomes relevant when people move from appetite peptides into gut-repair and intestinal-adaptation biology.
GLP-2 is an endogenous gut peptide involved in intestinal growth and barrier-related signaling and helps explain GLP-2 analog therapies.
GLP-2 tends to stay in the conversation because it touches a familiar public theme: intestinal growth, barrier function, and gut peptide. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Important human gut-peptide biology with clear translational relevance.
Human biology and analog-drug development are both relevant, but native GLP-2 should be kept distinct from teduglutide-like products.
Support spans gut physiology, mucosal biology, and intestinal-adaptation research.
Why this page carries the current tier: Important human gut-peptide biology with clear translational relevance.
The current seed trail for GLP-2 is pulling from 2 databases sources and 1 literature source.
Safety, limits, and regulatory context
The native hormone and drug analogs should be discussed separately to avoid overclaiming.
GLP-2 itself is tracked here as endogenous biology rather than a marketed drug.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for GLP-2. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for GLP-2 is CID 71300624. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 71300624
- Formula
- C165H254N44O55S
- Molecular weight
- 3766.1
- InChIKey
- TWSALRJGPBVBQU-PKQQPRCHSA-N
Matched synonyms include Glucagon-like peptide II, DTXSID50237869, Glucagon Like Peptide 2, RefChem:143585, Proglucagon (126-158), DTXCID50160360, Glucagon-Like Peptide-2 (1-33), 0825W549JC.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for GLP-2 returns 1435 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for GLP-2 returns 2018 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.